The proceeds will be used to accelerate the clinical development and commercialization of Foresight Diagnostics' cancer recurrence testing platform, PhasED-Seq™. "Foresite Capital brings significant operational and investment experience in cancer diagnostics and the minimal residual disease (MRD) market and are an excellent partner for us as we pursue our mission to improve the lives of cancer patients. This next chapter in our growth will be focused on expanding our support of pharmaceutical partners, furthering the clinical and regulatory claims associated with our platform, and bringing our tests to patients.